https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34089 Wed 31 Aug 2022 13:37:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54979 Wed 27 Mar 2024 09:31:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50479 72 hours with Injury Severity Score (ISS) of >15 were included. Patients were grouped based on number of repeat contrast studies received after initial imaging. Initial vital signs, resuscitation data, and laboratory parameters were collected. Primary outcome was AKI (Kidney Disease: Improving Global Outcomes criteria), and secondary outcomes included contrast-induced acute kidney injury (CI-AKI; >25% or >44 μmol/L increase in creatinine within 72 hours of contrast administration), multiple organ failure, length of stay, and mortality. Results: Six-hundred sixty-three multiple injury patients (age, 45.3 years [SD, 9.1 years]; males, 75%; ISS, 25 (interquartile range, 20–34); mortality, 5.4%) met the inclusion criteria. The incidence of AKI was 13.4%, and CI-AKI was 14.5%. Multivariate analysis revealed that receiving additional contrast doses within the first 72 hours was not associated with AKI (odds ratio, 1.33; confidence interval, 0.80–2.21; p = 0.273). Risk factors for AKI included higher ISS (p < 0.0007), older age (p = 0.0109), higher heart rate (p = 0.0327), lower systolic blood pressure (p = 0.0007), and deranged baseline blood results including base deficit (p = 0.0042), creatinine (p < 0.0001), lactate (p < 0.0001), and hemoglobin (p = 0.0085). Acute kidney injury was associated with worse outcomes (ICU length of stay: 8 vs. 3 days, p < 0.0001; mortality: 16% vs. 3.8%, p < 0.0001; MOF: 42% vs. 6.6%, p < 0.0001). Conclusion: There is a limited role of repeat contrast administration in AKI development in ICU-admitted multiple injury patients. The clinical significance of CI-AKI is likely overestimated, and it should not compromise essential secondary imaging from the ICU. Further prospective studies are needed to verify our results. Level of Evidence: Therapeutic/Care Management; Level III.]]> Wed 26 Jul 2023 18:08:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51839 Wed 20 Sep 2023 16:12:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40887 Wed 20 Jul 2022 10:39:49 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40827 Wed 13 Mar 2024 08:04:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16783 Wed 11 Apr 2018 17:18:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25637 Wed 11 Apr 2018 15:50:24 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30375 n = 6492) from New South Wales government schools, this study investigated the occupational and educational aspirations of 432 Indigenous school students. While we found that Indigenous and non-Indigenous students held similar occupational aspirations, Indigenous students were much less likely to aspire to attend university. Most starkly, high-achieving Indigenous students were significantly less likely to aspire to university than their high-achieving non-Indigenous peers. Given this evidence, we argue that both the possibility and desirability of higher education must be addressed if the widening participation agenda is to meet equity targets for Indigenous students.]]> Wed 11 Apr 2018 14:19:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16758 Wed 11 Apr 2018 12:47:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27254 Wed 11 Apr 2018 11:55:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34499 Wed 04 Dec 2019 11:34:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20161 Tue 24 Aug 2021 14:24:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54313 Tue 20 Feb 2024 14:29:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47053 Tue 13 Dec 2022 15:25:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4312 Thu 20 Jul 2023 16:32:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48041 Thu 16 Feb 2023 13:59:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46986 Thu 06 Jul 2023 15:13:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21000 p = <0.01), indicating that for every one point increase in implementation score, ECEC services were 38% more likely to be fully implementing the policies and practices. The findings highlight the opportunities for improving implementation of obesity prevention interventions in this setting by developing interventions that address such factors.]]> Sat 24 Mar 2018 07:50:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39018 2DS₂-VA scheme, were calculated. Factors associated with AF were assessed using logistic regression. Results: From 2000 to 2015, a total of 1827 women with AF were identified. AF prevalence increased every year as women aged from 2.71% (95% CI 1.62%–3.80%) in 2000 among women aged 74–79 years to 24.83% (95% CI = 23.23%–26.44%) in 2015 among women aged 89–94 years. The incidence proportion remained constant (between 3% and 5%) throughout the study period. Sedentary lifestyle (OR = 1.24, 95% CI = 1.04–1.49), hypertension (OR = 1.24, 95% CI = 1.09–1.42), arthritis (OR = 1.24, 95% CI = 1.09–1.41), heart attack (OR = 1.62, 95% CI = 1.18–2.24), and angina (OR = 1.39, 95% CI = 1.14–1.70) were independently associated with AF. Mean CHA₂DS₂-VA score for women with AF was 3.43 (SD ± 1.23). Conclusions: The prevalence of AF reported in Australian women is among the highest compared to previous estimations from other countries and regions. According to the findings, about one in four women over the age of 90 years had AF. These women were also at high risk of stroke. This has significant public health implications especially with changing demographics of increase in the aging population. Further research is required on understanding how women with AF are treated in Australia and their health outcomes.]]> Mon 29 Jan 2024 17:43:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36986 Mon 27 Jul 2020 15:43:48 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51980 Mon 25 Sep 2023 12:09:03 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35059 Mon 17 Jun 2019 11:20:45 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46241 N = 1432 women diagnosed with AF from 2000 to 2015 of the old cohort (born 1921–26) of the Australian Longitudinal Study on Women’s Health (ALSWH) who remained alive for at least 12 months post first recorded AF diagnosis. Self-reported data on demographics, health behaviours, health conditions, and SF-36 were obtained from the ALSWH surveys, corresponding to within three years of the date of the first record of AF diagnosis. Linked Pharmaceutical Benefits Scheme (PBS) data determined the use of oral anticoagulants and comorbid conditions, included in CHA₂DS₂-VA (Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes, Stroke or TIA, Vascular disease and Age 65–74 years) score calculation, were assessed using state-based hospital admissions data. Utility scores were calculated for every woman from their SF-36 responses using the SF-6D algorithm with Australian population norms. Mean utility scores were then calculated for women with various demographic, health behaviours, and clinical characteristics. Ordinary Least Square (OLS) regression modelling was performed to determine factors associated with these utility scores. Two different scenarios were used for the analysis: (1) complete-case, for women with complete data on all the SF-36 items required to estimate SF-6D (N = 584 women), and (2) Multiple Imputation (MI) for missing data, applied to missing values on SF-36 items (N = 1432 women). MI scenario was included to gauge the potential bias when using complete data only. Results: The mean health utility was estimated to be 0.638 ± 0.119 for the complete dataset and 0.642 ± 0.120 for the dataset where missing values were handled using MI. Using the MI technique, living in regional and remote areas (β=0.016±0.007) and the use of oral anticoagulants (β=0.021±0.007) were positively associated with health utility compared to living in major cities and no use of anticoagulants, respectively. Difficulty to manage on available income (β=−0.027±0.009), no/low physical activity (β=−0.069±0.011), disability (β=−0.097±0.008), history of stroke (β=−0.025±0.013) and history of arthritis (β=−0.024±0.007) were negatively associated with health utility. Conclusion: This study presents health utility estimates for older women with AF. These estimates can be used in future clinical and economic research. The study also highlights better health utilities for women living in regional and remote areas, which requires further exploration.]]> Mon 14 Nov 2022 13:17:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50968 Mon 14 Aug 2023 15:20:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44215 85% for most of the latent statuses. All factors but diabetes mellitus among the CHA2DS2-VA scoring scheme were independently associated with latent status membership at the time of AF diagnosis. Conclusions: Evaluation of pharmacological treatment indicates that prevention of thromboembolism is inadequate among women with AF. There exists wide variations in medication patterns. However, once in a particular pattern, women are likely to continue the same medications long-term. This underscores the importance of initial assessment of patient profile and stroke risk score in determining the treatment for AF. Failure to assess risk makes women susceptible to devastating AF complications.]]> Mon 10 Oct 2022 16:52:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50552 Fri 28 Jul 2023 10:31:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52806 Fri 27 Oct 2023 14:20:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42278 20 mSv). The study cohort included 428 patients (193 male and 235 female) with an average age of 44 years (±28). There were 447 procedures performed, i.e., all involved operative fluoroscopy, 116 involved computed tomography, and 397 involved X-ray. The mean cumulative effective dose per patient was 1.96 mSv (±4.98, 45.12). The mean cumulative effective dose for operative fluoroscopy was 0.32 mSv (±0.73, 5.91), for X-ray was 1.12 mSv (±3.6, 39.23) and for computed tomography was 2.22 mSv (±4.13, 20.14). The mean cumulative effective dose of 1.96 mSv falls below the recommended maximum annual exposure of 20 mSv. This study can serve as a guide for informing clinicians and patients of the acceptable radiation risk in the context of isolated extremity trauma.]]> Fri 19 Aug 2022 14:51:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50542 Fri 18 Aug 2023 12:00:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51692 Fri 15 Sep 2023 09:44:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41778 Fri 12 Aug 2022 12:03:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55056 Fri 05 Apr 2024 14:28:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39971 Fri 01 Jul 2022 09:16:31 AEST ]]>